leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...202203204205206207208209210211212...235236»
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Metastases:  Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 17, 2016   
    P1/2,  N=24, Recruiting, 
    Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: May 2016 --> May 2018
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Metastases:  Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 17, 2016   
    P2,  N=120, Recruiting, 
    Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Apr 2016 --> Jul 2016
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Trial initiation date, Surgery:  Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining (clinicaltrials.gov) -  Jan 4, 2016   
    P=N/A,  N=40, Recruiting, 
    Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Nov 2015 --> Jun 2015
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Enrollment open, Trial initiation date, Surgery:  Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining (clinicaltrials.gov) -  Dec 30, 2015   
    P=N/A,  N=40, Recruiting, 
    Trial primary completion date: Jan 2017 --> Jan 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Nov 2015
  • ||||||||||  Reolysin (pelareorep) / Oncolytics, Andrus Reo
    Enrollment open, PD(L)-1 Biomarker, Metastases:  Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) -  Dec 29, 2015   
    P1,  N=9, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial completion, Trial primary completion date, Metastases:  Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) -  Dec 25, 2015   
    P1,  N=16, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015
  • ||||||||||  Trial primary completion date, Metastases:  Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) -  Dec 23, 2015   
    P2,  N=32, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2016
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
    Enrollment closed, Trial primary completion date, Metastases:  METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) -  Dec 18, 2015   
    P2,  N=256, Active, not recruiting, 
    N=50 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2015; Slow accrual Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2016
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Combination therapy:  FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) -  Dec 15, 2015   
    P1/2,  N=25, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Sep 2013 --> Sep 2016
  • ||||||||||  leucovorin calcium / Generic mfg.
    Enrollment change:  A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) -  Dec 12, 2015   
    P2,  N=99, Terminated, 
    Trial primary completion date: Dec 2015 --> Mar 2016 N=160 --> 99
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial primary completion date, Combination therapy, Metastases:  Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) -  Dec 10, 2015   
    P2,  N=375, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2016 Trial primary completion date: Mar 2015 --> Mar 2016